RGLS Regulus Therapeutics Inc. Stock Quote

RGLS [NASD]

Index	-	P/E	-	EPS (ttm)	-0.29	Insider Own	0.40%	Shs Outstand	145.97M	Perf Week	-13.97%
Market Cap	326.40M	Forward P/E	-	EPS next Y	-0.20	Insider Trans	24.30%	Shs Float	139.78M	Perf Month	-28.84%
Income	-28.50M	PEG	-	EPS next Q	-0.05	Inst Own	45.30%	Short Float	2.18%	Perf Quarter	-30.54%
Sales	-	P/S	-	EPS this Y	27.90%	Inst Trans	86.95%	Short Ratio	14.38	Perf Half Y	-36.58%
Book/sh	0.34	P/B	6.09	EPS next Y	4.80%	ROA	-51.40%	Target Price	1.50	Perf Year	-74.92%
Cash/sh	0.34	P/C	6.06	EPS next 5Y	39.60%	ROE	-67.10%	52W Range	1.58 - 8.72	Perf YTD	-34.29%
Dividend	-	P/FCF	-	EPS past 5Y	55.50%	ROI	-	52W High	-76.27%	Beta	2.07
Dividend %	-	Quick Ratio	12.30	Sales past 5Y	-	Gross Margin	-	52W Low	31.35%	ATR	0.31
Employees	25	Current Ratio	12.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	39.95	Volatility	12.34% 11.60%
Optionable	Yes	Debt/Eq	0.09	EPS Q/Q	45.40%	Profit Margin	-	Rel Volume	0.18	Prev Close	2.07
Shortable	Yes	LT Debt/Eq	0.07	Earnings	May 12 AMC	Payout	-	Avg Volume	212.09K	Price	2.07
Recom	2.30	SMA20	-17.48%	SMA50	-11.41%	SMA200	-39.40%	Volume	39,226	Change	0.00%

Mar-28-18

Initiated

B. Riley FBR, Inc.

Neutral

Jan-05-18

Initiated

Leerink Partners

Outperform

Jun-13-17

Reiterated

Chardan Capital Markets

Buy

$5 → $2.50

Mar-06-17

Reiterated

Wedbush

Outperform

$8 → $6

Jan-30-17

Downgrade

Wells Fargo

Outperform → Market Perform

Jan-30-17

Downgrade

Needham

Buy → Hold

Dec-07-16

Reiterated

Chardan Capital Markets

Buy

$12 → $5

Nov-02-16

Reiterated

Needham

Buy

$10 → $9

Jul-25-16

Reiterated

Chardan Capital Markets

Buy

$14.50 → $12

Jun-28-16

Reiterated

Needham

Buy

$25 → $10

Jun-28-16

Reiterated

FBR Capital

Outperform

$30 → $9

Jun-28-16

Reiterated

Chardan Capital Markets

Buy

$20 → $13.50

Jun-07-16

Reiterated

Chardan Capital Markets

Buy

$15 → $20

Apr-13-16

Initiated

Chardan Capital Markets

Buy

$15

Dec-04-15

Initiated

Wells Fargo

Outperform

Jun-09-15

Initiated

Guggenheim

Buy

Apr-21-15

Resumed

FBR Capital

Outperform

$30

Nov-24-14

Initiated

Deutsche Bank

Buy

$30

Aug-07-14

Reiterated

FBR Capital

Outperform

$14 → $15

Aug-14-13

Reiterated

Needham

Buy

$8 → $12

Jun-21-22 08:00AM	Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire
Jun-13-22 08:00AM	Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire
Jun-02-22 08:00AM	Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK PR Newswire
May-17-22 04:30PM	Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference PR Newswire +6.56%
07:00AM	7 Penny Stocks With 10x Potential This Year InvestorPlace
May-12-22 04:05PM	Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates PR Newswire -7.67%
10:20AM	Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug Zacks
May-11-22 08:00AM	Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire +54.83%
May-05-22 04:05PM	Regulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference Call PR Newswire -6.41%
Mar-24-22 12:03PM	Regulus Starts Preclinical Studies In ALS Under Pact With Brigham and Women's Hospital Benzinga
08:00AM	Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital PR Newswire
Mar-10-22 04:05PM	Regulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Updates PR Newswire
Mar-03-22 05:15PM	Regulus Therapeutics Announces Timing for Fourth Quarter and Year-End 2021 Financial Results Webcast and Conference Call PR Newswire -5.28%
Feb-24-22 08:00AM	Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome PR Newswire
Feb-10-22 04:30PM	Regulus Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference PR Newswire
Jan-26-22 10:00AM	Regulus (RGLS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? Zacks
Jan-20-22 05:18PM	Regulus Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA for RGLS8429 PR Newswire
Jan-19-22 09:38AM	Asymmetry Capital Management, L.P. Buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, ... GuruFocus.com -7.83%
Jan-04-22 08:00AM	Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference PR Newswire
Dec-03-21 08:30AM	Regulus Appoints Mohammad Ahmadian, Ph.D., as Vice President, Chemistry and Pharmaceutical Development PR Newswire -6.85%
Dec-01-21 08:30AM	Regulus Therapeutics Announces Presentation at the First Annual Rare & Genetic Kidney Disease Drug Development Summit PR Newswire -6.55%
Nov-30-21 05:23PM	Regulus Therapeutics Announces Closing of $34.6 Million Private Placement of Equity PR Newswire
Nov-24-21 04:05PM	Regulus Therapeutics Announces Private Placement of Equity PR Newswire +8.68%
Nov-10-21 05:45PM	Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates Zacks -5.58%
04:05PM	Regulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent Updates PR Newswire
Nov-03-21 05:15PM	Regulus Therapeutics Announces Timing for Third Quarter 2021 Financial Results Webcast and Conference Call PR Newswire
Oct-28-21 03:05PM	Analysts Estimate Regulus (RGLS) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-13-21 03:11PM	Mid-Afternoon Market Update: Nasdaq Jumps 100 Points; Jasper Therapeutics Shares Spike Higher Benzinga -29.88%
12:27PM	Mid-Day Market Update: Gold Surges 2%; Neuronetics Shares Plunge Benzinga
07:27AM	20 Stocks Moving in Wednesday's Pre-Market Session Benzinga
Oct-12-21 04:05PM	Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney Disease PR Newswire
Sep-30-21 04:45PM	Regulus Therapeutics' Director David Baltimore Receives 2021 Lasker-Koshland Special Achievement Award in Medical Science PR Newswire
Sep-09-21 04:40PM	Regulus Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire
Sep-06-21 02:33PM	Is Regulus Therapeutics (NASDAQ:RGLS) Using Too Much Debt? Simply Wall St.
Aug-10-21 05:55PM	Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:05PM	Regulus Therapeutics Reports Second Quarter 2021 Financial Results and Recent Updates PR Newswire
Aug-03-21 05:15PM	Regulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results Webcast and Conference Call PR Newswire
Jun-30-21 09:33AM	Is Regulus Therapeutics Inc (RGLS) A Good Stock To Buy? Insider Monkey
Jun-25-21 01:38PM	Regulus Therapeutics Presents Additional Data From Rare Kidney Disease Program Benzinga -8.50%
07:05AM	Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021 PR Newswire
Jun-21-21 07:00AM	Regulus Therapeutics to Present Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021 PR Newswire +13.20%
Jun-11-21 08:56AM	Do Options Traders Know Something About Regulus Therapeutics (RGLS) Stock We Don't? Zacks
May-21-21 10:47AM	Regulus's Polycystic Kidney Disease Candidate Shows Benefit At Interim Analysis Benzinga
08:07AM	Regulus Therapeutics Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program PR Newswire
May-14-21 04:07PM	Regulus Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit PR Newswire +7.32%
May-13-21 05:35PM	Regulus (RGLS) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:07PM	Regulus Therapeutics Reports First Quarter 2021 Financial Results and Recent Updates PR Newswire
03:15PM	Regulus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-06-21 03:01PM	Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks -8.74%
May-03-21 09:25AM	Regulus Therapeutics' RGLS4326 Reports Mixed Bag On Polycystic Kidney Disease-Associated Biomarker Study Benzinga -19.42%
08:00AM	Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire
Apr-15-21 08:07AM	Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire
Apr-07-21 08:07AM	Regulus Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference PR Newswire
Mar-10-21 04:03AM	Investors Who Bought Regulus Therapeutics (NASDAQ:RGLS) Shares A Year Ago Are Now Up 101% Simply Wall St.
Mar-09-21 04:07PM	Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Updates PR Newswire +7.03%
Mar-05-21 04:07PM	Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference PR Newswire +13.04%
Mar-04-21 12:30PM	Will Regulus (RGLS) Report Negative Q4 Earnings? What You Should Know Zacks -9.45%
Feb-10-21 08:07AM	Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire
Jan-27-21 08:07AM	Regulus Announces Addition to Board of Directors PR Newswire -10.32%
Jan-05-21 08:07AM	Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference PR Newswire
Dec-09-20 08:54AM	Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock? Zacks
Dec-08-20 08:07AM	Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity PR Newswire +15.19%
Dec-02-20 07:00AM	Regulus Therapeutics Collaborates With Bio-Techne For Biomarker Development PR Newswire
Dec-01-20 08:35AM	Regulus Therapeutics Announces Private Placement of Equity PR Newswire +11.09%
Nov-29-20 02:33PM	Should I Buy Regulus Therapeutics Inc (RGLS)? Insider Monkey
Nov-05-20 05:25PM	Regulus (RGLS) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:07PM	Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates PR Newswire
Nov-03-20 12:31PM	Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Nov-02-20 08:07AM	Regulus Therapeutics Announces Achievement of Interim Enrollment Milestone Under Collaboration with Sanofi PR Newswire
Oct-15-20 08:07AM	Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire
Oct-13-20 08:07AM	Regulus Therapeutics Announces Receipt of $5 Million Milestone and Material Payments from Sanofi PR Newswire +8.38%
Sep-11-20 08:07AM	Regulus Therapeutics to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference PR Newswire
Sep-08-20 08:28AM	What You Need To Know About The Regulus Therapeutics Inc. (NASDAQ:RGLS) Analyst Downgrade Today Simply Wall St.
Sep-03-20 08:07AM	Regulus Therapeutics to Present at the 2020 Wells Fargo Virtual Healthcare Conference PR Newswire
Aug-31-20 08:07AM	Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements PR Newswire -7.00%
Aug-13-20 06:05PM	Regulus (RGLS) Reports Q2 Loss, Lags Revenue Estimates Zacks -6.10%
04:07PM	Regulus Therapeutics Reports Second Quarter 2020 Financial Results and Recent Updates PR Newswire
Aug-06-20 12:30PM	Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks -6.40%
08:07AM	Regulus Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference PR Newswire
Aug-03-20 08:07AM	Regulus Therapeutics Appoints Denis Drygin, Ph.D., as Chief Scientific Officer PR Newswire
Jul-29-20 08:07AM	Regulus Therapeutics Announces FDA Orphan Drug Designation of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire +5.23%
Jul-22-20 08:07AM	Regulus Therapeutics Completes Dosing in Phase 1 Multiple Ascending Dose Study of RGLS4326 in Healthy Volunteers for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire -11.58%
Jun-12-20 08:01AM	Analysts' Revenue Estimates For Regulus Therapeutics Inc. (NASDAQ:RGLS) Are Surging Higher Simply Wall St. +10.47%
May-14-20 04:07PM	Regulus Therapeutics Reports First Quarter 2020 Financial Results and Recent Updates PR Newswire
May-07-20 12:30PM	Regulus (RGLS) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Mar-12-20 04:37PM	Regulus Reports Fourth Quarter and Year-End 2019 Financial Results and Recent Updates PR Newswire -13.54%
Mar-09-20 12:30PM	Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks
Feb-13-20 04:30PM	Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD PR Newswire
Jan-21-20 07:47AM	How Regulus Therapeutics Inc. (NASDAQ:RGLS) Can Impact Your Portfolio Volatility Simply Wall St. +8.26%
Dec-22-19 07:44PM	Hedge Funds Are Dumping Regulus Therapeutics Inc (RGLS) Insider Monkey
Dec-16-19 08:00AM	Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326 PR Newswire -6.78%
Nov-18-19 08:07AM	Regulus Therapeutics to Present at the Stifel Healthcare Conference PR Newswire
Nov-15-19 01:37PM	Analysts Are Upgrading Regulus Therapeutics Inc. After Its Latest Results Simply Wall St. -5.78%
Nov-12-19 05:55PM	Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:05PM	Regulus Therapeutics Reports Third Quarter 2019 Financial Results and Recent Updates PR Newswire
Nov-07-19 10:30AM	Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-16-19 04:15PM	Regulus Therapeutics Presents Preclinical Data Identifying RGLS4326 as a Potential Disease-Modifying Treatment for Autosomal Dominant Polycystic Kidney Disease at OTS Annual Meeting PR Newswire
Sep-20-19 01:30PM	Some Regulus Therapeutics (NASDAQ:RGLS) Shareholders Have Copped A 99% Share Price Wipe Out Simply Wall St.
Sep-12-19 08:00AM	Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD PR Newswire
Sep-03-19 04:10PM	Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference PR Newswire

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Drygin Denis	Chief Scientific Officer	Feb 04	Buy	0.23	23,314	5,362	23,314	Feb 07 05:09 PM
Hagan Joseph P	President and CEO	Jan 26	Buy	0.22	100,000	21,520	417,006	Jan 26 04:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience